The METABOlomics Platform of the Luxembourg Institute of Health under leadership of Nathalie Legrave became a partner of NMC from 2025 onwards. In this position, Nathalie Legrave succeeds Johannes Meisner, who was appointed director of LIH's Department of Cancer Research in 2024. Johannes Meisner also leads the Cancer Metabolomics Group.The METABO platform is dedicated to the study of small molecules, specifically polar metabolites and lipids.Their work focuses on applying and advancing metabolomics approaches within biomedical research fields, particularly cancer research. Beyond utilising state-of-the-art metabolomics, they actively develop and implement novel analytical methods to expand metabolome coverage and support emerging research directions.
Find more information on the METABO platform, the Department of Cancer Research, and the Cancer Metabolomics Group and start connecting.
